HPM
Q1 2026 report
Revenue
3.27 m PLN
— YoY
Net income
-14.81 m PLN
— YoY
EBITDA
-6.22 m PLN
— YoY
FCF
-6.36 m PLN
— YoY
Summary
Investment thesis
- Rejestracja zakładu w amerykańskiej FDA (marzec 2026) otwiera realną drogę eksportu do USA
- Przychody rosną (+10,2% r/r), a wzrost kosztów operacyjnych jest wolniejszy niż wzrost sprzedaży
- Bardzo cienka poduszka kapitałowa (equity/aktywa 8,9%) wobec ogromnego zadłużenia inwestycyjnego (ok. 170,4 mln zł) zaciągniętego na budowę zakładu
- Tempo wypalania gotówki w I kw. 2026 (-53% w jednym kwartale) rodzi pytania o płynność w kolejnych okresach, jeśli nie zostanie potwierdzone jako jednorazowe
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
HPM · Q1 2026
| Metric | Q1 2026 | Q1 2025 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|
| Revenue | 3.27 | — | — | reported | — | 1.00 |
| EBITDA | -6.22 | — | — | reported | — | 0.90 |
| EBIT | -10.66 | — | — | reported | — | 1.00 |
| Net income | -14.81 | — | — | reported | — | 1.00 |
| EPS (basic) (PLN) | -10.95 | — | — | derived | — | 0.90 |
| D&A | 4.43 | — | — | reported | — | 1.00 |
| Interest expense | 2.04 | — | — | reported | — | 1.00 |
| Shares (basic) (m units) | 1.35 | — | — | reported | — | 1.00 |
| EBITDA margin | -172.6% | — | — | reported | — | 0.85 |
| EBIT margin | -295.5% | — | — | reported | — | 0.90 |
| Net margin | -410.6% | — | — | reported | — | 0.90 |
| Cash | 17.34 | — | — | reported | — | 1.00 |
| Total debt | 170.45 | — | — | derived | — | 0.90 |
| Net debt | 153.11 | — | — | derived | — | 0.90 |
| Equity | 20.47 | — | — | reported | — | 1.00 |
| Total assets | 229.73 | — | — | reported | — | 1.00 |
| Working capital | -9.42 | — | — | reported | — | 0.90 |
| Current assets | 28.12 | — | — | reported | — | 1.00 |
| Current liabilities | 37.54 | — | — | reported | — | 1.00 |
| CFO | -5.58 | — | — | reported | — | 1.00 |
| CapEx | 0.78 | — | — | reported | — | 1.00 |
| FCF | -6.36 | — | — | derived | — | 0.90 |
| Current ratio | 0.75x | — | — | reported | — | 0.90 |
| Quick ratio | 0.59x | — | — | reported | — | 0.85 |
| Cash ratio | 0.46x | — | — | reported | — | 0.90 |
| Debt / equity | 8.33x | — | — | reported | — | 0.85 |
| Debt / assets | 0.74x | — | — | reported | — | 0.85 |
| Net debt / equity | 7.48x | — | — | reported | — | 0.85 |
| Revenue growth (YoY) | 10.16% | — | — | reported | — | 0.90 |
| EBIT growth (YoY) | 0.65% | — | — | reported | — | 0.85 |
| Net income growth (YoY) | -41.63% | — | — | reported | — | 0.90 |
Q1 2026 · Δ YoY
Revenue
3.27
—
3.27
—
- Q1 2025
- —
EBITDA
-6.22
—
-6.22
—
- Q1 2025
- —
EBIT
-10.66
—
-10.66
—
- Q1 2025
- —
Net income
-14.81
—
-14.81
—
- Q1 2025
- —
EPS (basic)
(PLN)
-10.95
—
-10.95
—
- Q1 2025
- —
D&A
4.43
—
4.43
—
- Q1 2025
- —
Interest expense
2.04
—
2.04
—
- Q1 2025
- —
Shares (basic)
(m units)
1.35
—
1.35
—
- Q1 2025
- —
EBITDA margin
-172.6%
—
-172.6%
—
- Q1 2025
- —
EBIT margin
-295.5%
—
-295.5%
—
- Q1 2025
- —
Net margin
-410.6%
—
-410.6%
—
- Q1 2025
- —
Cash
17.34
—
17.34
—
- Q1 2025
- —
Total debt
170.45
—
170.45
—
- Q1 2025
- —
Net debt
153.11
—
153.11
—
- Q1 2025
- —
Equity
20.47
—
20.47
—
- Q1 2025
- —
Total assets
229.73
—
229.73
—
- Q1 2025
- —
Working capital
-9.42
—
-9.42
—
- Q1 2025
- —
Current assets
28.12
—
28.12
—
- Q1 2025
- —
Current liabilities
37.54
—
37.54
—
- Q1 2025
- —
CFO
-5.58
—
-5.58
—
- Q1 2025
- —
CapEx
0.78
—
0.78
—
- Q1 2025
- —
FCF
-6.36
—
-6.36
—
- Q1 2025
- —
Current ratio
0.75x
—
0.75x
—
- Q1 2025
- —
Quick ratio
0.59x
—
0.59x
—
- Q1 2025
- —
Cash ratio
0.46x
—
0.46x
—
- Q1 2025
- —
Debt / equity
8.33x
—
8.33x
—
- Q1 2025
- —
Debt / assets
0.74x
—
0.74x
—
- Q1 2025
- —
Net debt / equity
7.48x
—
7.48x
—
- Q1 2025
- —
Revenue growth (YoY)
10.16%
—
10.16%
—
- Q1 2025
- —
EBIT growth (YoY)
0.65%
—
0.65%
—
- Q1 2025
- —
Net income growth (YoY)
-41.63%
—
-41.63%
—
- Q1 2025
- —